IASLC Studying Impact of COVID-19 on International Lung Cancer Clinical Trial Enrollment, Mitigation Strategies

Cancer Clinical Trial Compensation: Undue or Long Overdue?

Revised U.S. Food and Drug Administration Trial Eligibility Guidance: A Major Step Toward Transforming Lung Cancer Clinical Trials

TKI Plus Checkpoint Inhibitor Without Chemotherapy Shows Promise as Initial Option in Advanced NSCLC

Co-mutations in DNA Damage-Response Pathways May Predict Effectiveness of Checkpoint Inhibitors in NSCLC

Translating Early Research to Adapt CAR T-Cell Therapy to Solid Tumors

Balancing the Benefits and Harms of Lung Cancer Screening

Advancing Combined Modality Therapy for Early-Stage, Screen-Detected Disease: Adjuvant/Neoadjuvant Therapy

Differences in Smoking and Lung Cancer Incidence Among Black and White Young Adults in the United States

Lung Cancer Screening in Poland Pilot Program Is Restarted After COVID-19 Lockdown

Should We Delay Lung Cancer Screening During the COVID-19 Pandemic?

Experts Discuss Benefits, Challenges with Lung Cancer Screening: A Pro/Con